文献速递类风湿关节炎

破骨细胞来源的自分泌运动因子是炎性骨丢失的区分因素

Osteoclast-Derived Autotaxin, a Distinguishing Factor for Inflammatory Bone Loss.
PubMed 文献 · Arthritis Rheumatol · 2019-09-30

该研究在鼠类关节炎模型中探索自分泌运动因子(ATX)在破骨细胞(OC)介导的骨侵蚀中的作用。药物抑制或OC条件性敲除ATX基因Ennp2可显著减轻局灶骨侵蚀和全身骨丢失,而不影响滑膜炎症。结果提示ATX是炎症诱导骨侵蚀的新OC因子,抑制ATX可能成为预防RA骨侵蚀的新治疗策略。

要点

  • 炎症部位OC过表达ATX,OC来源ATX促进OC骨吸收活性。
  • 药物抑制ATX在hTNF+/-小鼠中减少局灶骨侵蚀36%、全身骨丢失43%(P<0.05),不影响滑膜炎。
  • OC特异性敲除ATX可逆转LPS和K/BxN血清诱导的全身骨丢失(30%,P<0.01)和骨侵蚀(55%,P<0.001)。

核心结论

  • ATX是特异性控制炎症诱导骨侵蚀和全身骨丢失的新型破骨细胞因子,抑制ATX可能为预防RA患者骨侵蚀提供新治疗途径。

研究设计与样本

  • 采用药物抑制ATX及在鼠OC中条件性失活ATX基因Ennp2(ΔATXC tsk)两种策略。
  • 在人类肿瘤坏死因子转基因(hTNF+/-)小鼠和K/BxN血清转移诱导关节炎小鼠中研究关节炎和侵蚀性疾病。
  • 在脂多糖(LPS)诱导炎症和雌激素剥夺小鼠中分析全身骨丢失,并通过组织学和微计算机断层扫描评估关节炎症和骨侵蚀。
  • 在OC分化和活性实验中检测ATX在RA中的作用。

主要发现

  • 炎症部位存在的OC过表达ATX。
  • 在hTNF+/-小鼠中,与载体对照相比,药物抑制ATX显著减轻局灶骨侵蚀(减少36%;P<0.05)和全身骨丢失(减少43%;P<0.05),而不影响滑膜炎症。
  • OC来源ATX对OC骨吸收活性至关重要,并被TNF或LPS引发的炎症上调。
  • 在去卵巢小鼠中,OC特异性丢失ATX显著保护免受LPS和K/BxN血清治疗诱导的全身骨丢失和侵蚀(全身骨丢失逆转30%[P<0.01];侵蚀逆转55%[P<0.001]),但未赋予骨保护特性。

关键数值与推荐

  • 药物抑制ATX在hTNF+/-小鼠中减少局灶骨侵蚀36%(P<0.05)和全身骨丢失43%(P<0.05)。
  • OC特异性敲除ATX在去卵巢小鼠中逆转LPS和K/BxN血清诱导的全身骨丢失30%(P<0.01)和骨侵蚀55%(P<0.001)。

临床怎么用

  • 对于临床缓解或低疾病活动度但仍持续出现骨侵蚀的RA患者,抑制ATX可能成为长期抑制OC活性而不改变OC生理性骨重建功能的新选择。

局限性

  • 研究基于鼠类模型和体外OC实验,尚未在RA患者中验证ATX抑制的疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The severity of rheumatoid arthritis (RA) correlates directly with bone erosions arising from osteoclast (OC) hyperactivity. Despite the fact that inflammation may be controlled in patients with RA, those in a state of sustained clinical remission or low disease activity may continue to accrue erosions, which supports the need for treatments that would be suitable for long-lasting inhibition of OC activity without altering the physiologic function of OCs in bone remodeling. Autotaxin (ATX) contributes to inflammation, but its role in bone erosion is unknown. METHODS: ATX was targeted by inhibitory treatment with pharmacologic drugs and also by conditional inactivation of the ATX gene Ennp2 in murine OCs (ΔATXC tsk ). Arthritic and erosive diseases were studied in human tumor necrosis factor-transgenic (hTNF+/- ) mice and mice with K/BxN serum transfer-induced arthritis. Systemic bone loss was also analyzed in mice with lipopolysaccharide (LPS)-induced inflammation and estrogen deprivation. Joint inflammation and bone erosion were assessed by histology and micro-computed tomography. The role of ATX in RA was also examined in OC differentiation and activity assays. RESULTS: OCs present at sites of inflammation overexpressed ATX. Pharmacologic inhibition of ATX in hTNF+/- mice, as compared to vehicle-treated controls, significantly mitigated focal bone erosion (36% decrease; P < 0.05) and systemic bone loss (43% decrease; P < 0.05), without affecting synovial inflammation. OC-derived ATX was revealed to be instrumental in OC bone resorptive activity and was up-regulated by the inflammation elicited in the presence of TNF or LPS. Specific loss of ATX in OCs from mice subjected to ovariectomy significantly protected against the systemic bone loss and erosion that had been induced with LPS and K/BxN serum treatments (30% reversal of systemic bone loss [P < 0.01]; 55% reversal of erosion [P < 0.001]), without conferring bone-protective properties. CONCLUSION: Our results identify ATX as a novel OC factor that specifically controls inflammation-induced bone erosions and systemic bone loss. Therefore, ATX inhibition offers a novel therapeutic approach for potentially preventing bone erosion in patients with RA.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Flammier S, Peyruchaud O, Bourguillault F, et al. Osteoclast-Derived Autotaxin, a Distinguishing Factor for Inflammatory Bone Loss. Arthritis Rheumatol. 2019. PMID: 31162832. doi:10.1002/art.41005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。